PATH entered a three-party research collaboration agreement with the International AIDS Vaccine Initiative (IAVI) and its Human Immunology Laboratory (HIL) at Imperial College London in August 2012. The IAVI HIL was selected to be MVI’s Immunology Reference Center, based on their experience in performing immunological tests for the HIV field and the strength of their quality systems. Initial efforts at the center were focused on validating the IFN-γ ELISpot and ICS assays for samples from malaria vaccine trials. With these T cell assays now validated, the center has been performing them on samples from trials supported by MVI. Further, the IAVI HIL is working to develop, optimize, and validate serological assays, such as the ELISA, that are needed to support MVI clinical trials.